Get the Stockscreener App
14.19
4.25%
-0.63
After Hours:
14.26
0.07
+0.49%
Denali Therapeutics Inc stock is traded at $14.19, with a volume of 1.60M.
It is down -4.25% in the last 24 hours and up +7.34% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$14.82
Open:
$14.65
24h Volume:
1.60M
Relative Volume:
0.93
Market Cap:
$2.07B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-4.9789
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-8.04%
1M Performance:
+7.34%
6M Performance:
-11.03%
1Y Performance:
-49.25%
1-Day Range:
$14.17
$14.80
1-Week Range:
$14.17
$15.69
52-Week Range:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
14.19 | 2.14B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics' (DNLI) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
SCS Capital Management LLC Acquires New Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Graham Capital Management L.P. Purchases 22,299 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Trexquant Investment LP Purchases 52,568 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Yiheng Capital Management L.P. Reduces Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? - Yahoo Finance
Alliancebernstein L.P. Trims Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali Therapeutics Inc. stock go up in YEARWeekly Investment Recap & Weekly Momentum Picks - Lancaster City Council
Crestline Management LP Has $56.57 Million Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Denali Therapeutics stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight rating on Denali Therapeutics stock - Investing.com
How cyclical is Denali Therapeutics Inc.’s revenue streamMarket Rally & Fast Moving Market Watchlists - beatles.ru
Should I hold or sell Denali Therapeutics Inc. nowPortfolio Value Summary & Stock Market Timing Techniques - beatles.ru
ADAR1 Capital Management LLC Has $189,000 Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali Therapeutics Inc. stock hit new highs in YEARPortfolio Gains Report & Technical Pattern Based Buy Signals - beatles.ru
Will Denali Therapeutics Inc. benefit from AI trendsTrade Entry Report & Smart Allocation Stock Reports - classian.co.kr
Denali Therapeutics Inc. $DNLI Shares Sold by Northern Trust Corp - MarketBeat
Real time scanner hits for Denali Therapeutics Inc. explainedWeekly Stock Summary & Daily Stock Trend Reports - Newser
Is Denali Therapeutics Inc. stock entering bullish territoryForecast Cut & Safe Capital Allocation Plans - Newser
Walleye Capital LLC Grows Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Is Denali Therapeutics Inc. a momentum stockStop Loss & Reliable Intraday Trade Plans - خودرو بانک
Is Denali Therapeutics Inc. stock a smart retirement pick2025 Technical Patterns & Daily Growth Stock Tips - خودرو بانک
Denali Therapeutics Inc. stock trendline breakdown2025 Technical Overview & Fast Entry High Yield Stock Tips - Newser
Is Denali Therapeutics Inc. a candidate for recovery playJuly 2025 News Drivers & Risk Adjusted Swing Trade Ideas - Newser
Is Denali Therapeutics Inc. subject to activist investor interestJuly 2025 Volume & Daily Growth Stock Investment Tips - خودرو بانک
Quantitative breakdown of Denali Therapeutics Inc. recent move2025 Key Lessons & Free Accurate Trade Setup Notifications - Newser
Denali Therapeutics Inc. stock trend outlook and recovery path2025 Analyst Calls & Consistent Growth Equity Picks - Newser
Hsbc Holdings PLC Buys 24,613 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
How to escape a deep drawdown in Denali Therapeutics Inc.Analyst Downgrade & Weekly High Return Stock Forecasts - Newser
Resistance Break Could Fuel Denali Therapeutics Inc. RallyJuly 2025 Weekly Recap & Consistent Profit Trade Alerts - beatles.ru
Risk adjusted return profile for Denali Therapeutics Inc. analyzedTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
Is Denali Therapeutics Inc.’s growth already priced in2025 Year in Review & Stepwise Entry and Exit Trade Signals - خودرو بانک
Using data filters to optimize entry into Denali Therapeutics Inc.Trade Volume Summary & Daily Chart Pattern Signals - Newser
Pattern recognition hints at Denali Therapeutics Inc. upside2025 Market Overview & Weekly High Return Opportunities - Newser
Market reaction to Denali Therapeutics Inc.’s recent newsJuly 2025 EndofMonth & Reliable Trade Execution Plans - Newser
American Century Companies Inc. Has $4.75 Million Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
What’s the analyst consensus on Denali Therapeutics Inc.July 2025 Chart Watch & Real-Time Stock Movement Alerts - خودرو بانک
Is Denali Therapeutics Inc. part of any major indexJuly 2025 Spike Watch & Verified Swing Trading Watchlists - خودرو بانک
What to do if you’re stuck in Denali Therapeutics Inc.Weekly Trade Recap & Free Low Drawdown Momentum Trade Ideas - Newser
News impact scoring models applied to Denali Therapeutics Inc.July 2025 Reactions & Weekly Hot Stock Watchlists - Newser
Key resistance and support levels for Denali Therapeutics Inc.Global Markets & Low Risk Growth Stock Ideas - Newser
Risk vs reward if holding onto Denali Therapeutics Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser
Using Ichimoku Cloud for Denali Therapeutics Inc. technicalsMarket Trend Review & Community Shared Stock Ideas - Newser
Relative strength of Denali Therapeutics Inc. in sector analysis2025 AllTime Highs & Low Risk Growth Stock Ideas - Newser
Heatmap analysis for Denali Therapeutics Inc. and competitors2025 Earnings Surprises & Technical Buy Zone Confirmations - Newser
Published on: 2025-09-03 03:03:45 - Newser
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):